HOME >> BIOLOGY >> NEWS
Gene therapy shown to protect and reverse the debilitating effects of Parkinson's disease in pre-clinical studies

Researchers at Rush-Presbyterian-St. Luke's Medical Center, Chicago, and Lausanne, Switzerland, have successfully used gene therapy to reverse the anatomical, cellular changes that occur in the brains of primates with Parkinson's disease. The researchers also report success in preventing the disease from progressing and reversing functional deficits or symptoms associated with the disease in monkeys displaying early signs of Parkinson's disease.

Results of the research are published in the Oct. 27 issue of the journal Science.

Rush scientists used a special virus (lenti-GDNF), which was developed by colleagues in Switzerland to deliver the gene for glial-derived neurotrophic factor (GDNF) directly to the brain cells of monkeys.

GDNF is a nutrient that strengthens and protects brain cells that would normally die in this disease. GDNF also increases production of the chemical neurotransmitter dopamine, which sends signals in the brain that enable people to move smoothly and normally. The loss of dopamine in the brain causes the symptoms of Parkinson's disease.

"The lentiviral vector delivery system was effective in getting GDNF to the specific sites needed to rescue the cells and enhance the production of dopamine. By giving GDNF, we can stimulate dopamine production and prevent both the structural and functional consequences of cell degeneration that are characteristic of Parkinson's disease," said Jeffrey H. Kordower, PhD, the principal author of study. He is professor of neurological sciences and director of the Research Center for Brain Repair at Rush-Presbyterian-St. Luke's Medical Center in Chicago. Study collaborators at the Lausanne University Medical School are Patrick Aebischer, MD, PhD, and Nicole Dglon. PhD.

Two groups of monkeys were involved in the research. The first group was studied to determine if and how the lentivirus delivery system affected the anatomy of the aged brain cells. The second group was
'"/>

Contact: John Pontarelli
jpontare@rush.edu
312-942-5949
Rush University Medical Center
26-Oct-2000


Page: 1 2 3 4

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2019)... (PRWEB) , ... March 07, 2019 , ... A firm ... to The Leukemia & Lymphoma Society (LLS). This donation will help fund not only ... patients and their families. , “We are always on the lookout for ways ...
(Date:3/9/2019)... ... March 09, 2019 , ... ... hM4Di ligands – exciting compounds for scientists studying GPCR and DREADD signalling. Hello ... and the National Institute of Neurological Disorders and Stroke, both institutes of the ...
(Date:2/27/2019)... ... 2019 , ... Fluxion Biosciences, a leading developer of precision solutions for life ... grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant ... Dr. Omar Mian at the Cleveland Clinic. , Liquid biopsies offer the potential to ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... ... solution for preclinical research organizations. It is a low code, GDPR/21 CFR ... and facilities, innovative technology-driven automated data capture and seamless data and information ...
(Date:3/11/2019)... ... , ... USDM Life Sciences and Generis have partnered ... GxP compliance for the life sciences industry. USDM Cloud Assurance delivers a ... for Generis’ flagship product, CARA. , Presentation One:, What: Cloud ...
(Date:3/5/2019)... ... March 05, 2019 , ... Modality Solutions, ... with regulatory filing authorities, logistics network experts, and experienced integrated staffing professionals. ... in the Inc. Verified Profile program, Inc. editors independently reviewed the Houston-based cold ...
(Date:2/26/2019)... ... February 26, 2019 , ... The idea for ... Villani developed the Visikol® tissue clearing technology for improved tissue characterization. From this ... products focused company to primarily a services focused company. , Today, Visikol ...
Breaking Biology Technology:
Cached News: